108 related articles for article (PubMed ID: 21992082)
21. Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.
Spindeldreier K; Thiesen J; Lipp HP; Krämer I
J Oncol Pharm Pract; 2014 Jun; 20(3):183-9. PubMed ID: 23812666
[TBL] [Abstract][Full Text] [Related]
22. Update on adverse drug events associated with parenteral iron.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
[TBL] [Abstract][Full Text] [Related]
23. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
24. Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions.
Kaiser J; Krämer I
J Oncol Pharm Pract; 2012 Jun; 18(2):213-21. PubMed ID: 22075005
[TBL] [Abstract][Full Text] [Related]
25. Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.
Philipp E; Braitsch M; Bichsel T; Mühlebach S
Eur J Hosp Pharm; 2016 Jan; 23(1):22-27. PubMed ID: 26835007
[TBL] [Abstract][Full Text] [Related]
26. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
27. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
28. Stability of Ibuprofen solutions in normal saline or 5% dextrose in water.
Walker SE; Choudhury J; Law S; Iazzetta J
Can J Hosp Pharm; 2011 Sep; 64(5):354-61. PubMed ID: 22479088
[TBL] [Abstract][Full Text] [Related]
29. Stability of ranitidine in intravenous admixtures stored frozen, refrigerated, and at room temperature.
Stewart JT; Warren FW; Johnson SM; Galante LJ
Am J Hosp Pharm; 1990 Sep; 47(9):2043-6. PubMed ID: 2220860
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
31. Long-term stability of morphine hydrochloride in 0.9% NaCl infusion polyolefin bags after freeze-thaw treatment and in polypropylene syringes at 5 degrees C + 3 degrees C.
Hecq JD; Godet M; Gillet P; Jamart J; Galanti L
Int J Pharm Compd; 2014; 18(1):78-82. PubMed ID: 24881344
[TBL] [Abstract][Full Text] [Related]
32. Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection.
Lam NP; Kennedy PE; Jarosinski PF; Gallelli JF
Am J Hosp Pharm; 1991 Feb; 48(2):280-2. PubMed ID: 2003500
[TBL] [Abstract][Full Text] [Related]
33. Stability of nizatidine in commonly used intravenous fluids and containers.
Raineri DL; Cwik MJ; Rodvold KA; Deyo KL; Scaros LP; Fischer JH
Am J Hosp Pharm; 1988 Jul; 45(7):1523-9. PubMed ID: 3137816
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
35. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
36. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
37. Physical and chemical stability of esomeprazole sodium solutions.
Kupiec TC; Aloumanis V; Ben M; Trissel LA; Chan P; Patterson J
Ann Pharmacother; 2008 Sep; 42(9):1247-51. PubMed ID: 18614750
[TBL] [Abstract][Full Text] [Related]
38. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Warady BA; Seligman PA; Dahl NV
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1140-6. PubMed ID: 17942782
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
Panesar A; Agarwal R
Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
[TBL] [Abstract][Full Text] [Related]
40. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
